30. Dementie

go back to reference Banerjee S, Hellier J, Dewey M, Romeo R, Ballard C, Baldwin R, et al. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet 2011;378:403-11.PubMedCrossRef Banerjee S, Hellier J, Dewey M, Romeo R, Ballard C, Baldwin R, et al. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet 2011;378:403-11.PubMedCrossRef

go back to reference Birks J, Grimley Evans J, Iakovidou V, Tsolaki M, Holt FE. Rivastigminefor Alzheimer’s disease. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD001191. Birks J, Grimley Evans J, Iakovidou V, Tsolaki M, Holt FE. Rivastigminefor Alzheimer’s disease. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD001191.

go back to reference Farlow MR, Cummings JL. Effective pharmacologic management of Alzheimer’s disease. Am J Med 2007;120:388-97.PubMedCrossRef Farlow MR, Cummings JL. Effective pharmacologic management of Alzheimer’s disease. Am J Med 2007;120:388-97.PubMedCrossRef

go back to reference Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, et al. Donepezil and memantine for moderate-to-severe Alzheimer’s disease. NEJM 2012;366: 893-903.PubMedCrossRef Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, et al. Donepezil and memantine for moderate-to-severe Alzheimer’s disease. NEJM 2012;366: 893-903.PubMedCrossRef

go back to reference Iliffe S. The National Institute for Health and Clinical Excellence (NICE) and drug treatment for Alzheimer’s disease. CNS Drugs 2007; 21:177-84.PubMedCrossRef Iliffe S. The National Institute for Health and Clinical Excellence (NICE) and drug treatment for Alzheimer’s disease. CNS Drugs 2007; 21:177-84.PubMedCrossRef

go back to reference Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 2002;41:719-39.PubMedCrossRef Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 2002;41:719-39.PubMedCrossRef

go back to reference Liepelt I, Maetzler W, Blaicher HP, Gasser T, Berg D. Treatment of dementia in parkinsonian syndromes with cholinesterase inhibitors. Dement Geriatr Cogn Disord 2007;23:351-67.PubMedCrossRef Liepelt I, Maetzler W, Blaicher HP, Gasser T, Berg D. Treatment of dementia in parkinsonian syndromes with cholinesterase inhibitors. Dement Geriatr Cogn Disord 2007;23:351-67.PubMedCrossRef

go back to reference Overshott R, Karim S, Burns A. Cholinesterase-inhibitors for delirium. Cochrane Database Syst Rev. 2008;(1):CD005317. Overshott R, Karim S, Burns A. Cholinesterase-inhibitors for delirium. Cochrane Database Syst Rev. 2008;(1):CD005317.

go back to reference Richard E, Heuvel E van den, Moll van Charante EP, Achthoven L, Vermeulen M, Bindels PJ, et al. Prevention of dementia by intensive vascular care (PreDIVA): a cluster-randomized trial in progress. Alzheimer Dis Assoc Disord. 2009;23:198-204.PubMedCrossRef Richard E, Heuvel E van den, Moll van Charante EP, Achthoven L, Vermeulen M, Bindels PJ, et al. Prevention of dementia by intensive vascular care (PreDIVA): a cluster-randomized trial in progress. Alzheimer Dis Assoc Disord. 2009;23:198-204.PubMedCrossRef

go back to reference Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase-inhibitors for DLB, PDD and CIND-PD. Cochrane Database Syst Rev 2012;3: CD006504. Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase-inhibitors for DLB, PDD and CIND-PD. Cochrane Database Syst Rev 2012;3: CD006504.